# US 8,772,368 B2 · Bioabsorbable blend for temporary scaffolding of the blood vessel wall > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,772,368 B2 - Document ID: US8772368B2 - Status: Granted - Kind: B2 - Application number: 14/023,784 - Filed: 2013-09-11 - Published: 2014-01-09 - Granted: 2014-07-08 - Earliest claimed: 2008-09-24 - Assignees: Hyung IL Kim; Kazuhiko Ishihara; Suntech, Inc. - Applicants: Suntech Co., Ltd. - Inventors: Hyung-Il Kim; Kazuhiko Ishihara - Web page: https://patentgrep.com/patent/US8772368B2 ## CPC - A61L 31/041: {Mixtures of macromolecular compounds} - A61L 27/26: Mixtures of macromolecular compounds - A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)} - A61L 31/148: {Materials at least partially resorbable by the body} - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers - A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers - A61F 2/82: Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07) - A61F 2210/0004: bioabsorbable - A61L 27/14: Macromolecular materials - A61L 2300/80: characterised by a special chemical form - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) ## Abstract A bioabsorbable blend comprising poly(L-lactide) (PLLA) and a phosphorylcholine group-containing copolymer (PPCP) capable of enduring the mechanical strength of blood vessel walls and applicable for fabricating cardiovascular devices was developed. The blend acts as a scaffold to support blood vessel walls during vascular healing and undergoes biodegradation in vivo after vascular healing is complete. Furthermore, the blend can prevent the formation and adsorption of thrombi. ## Claims ### Claim 1 A bioabsorbable stent, wherein the bioabsorbable stent is made from a blend, the blend comprising a biodegradable material and a phosphorylcholine group-containing copolymer (PPCP), wherein the biodegradable material is a bioabsorbable polymer comprising L-lactic acid. ### Claim 2 (depends on 1) The bioabsorbable stent of claim 1, wherein the PPCP is a water-soluble amphiphilic copolymer. ### Claim 3 (depends on 1) The bioabsorbable stent of to claim 1, wherein the PPCP is prepared by copolymerization of a 2-methacryloyloxethyl phosphoroylcholine (MPC) unit with a monomer selected from the group consisting of methyl methacrylate (MMA), ethyl methacrylate (EMA), butyl methacrylate (BMA), 2-ethylhexyl methacrylate (EHMA), lauryl methacrylate (LMA), hydroxyl-ethyl methacrylate (HEMA), choline methacrylate (CMA), poly(ethylene gycol) acrylate (PEGA), PEG methacrylate, 2-(methacryloxy)ethyl phosphorylcholine (MFC), N-vinyl pyrrolidone (VP), methacrylic acid (MA), acrylic acid (AA), hydroxypropyl methacrylate (HPMA), hydroxypropyl methacrylamide, 3-trimethylsilyl-propyl methacrylate (TMSPMA), p-nitrophenyloxycarbonyl(polyoxyethylene) methacrylate (MEONP), N-isopropylacrylamide (NIPAM), N-octyl acrylamide, and a combination thereof. ### Claim 4 (depends on 1) The bioabsorbable stent of to claim 1, wherein the PPCP is selected from the group consisting of poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) (PMB), poly(MPC-co-BMA-co-methacrylic acid) (PMBAc), poly(MPC-co-BMA), poly(MPC-co-BMA-co-MEONP) (PMBN), and poly(MPC-co-n-octylacrylamide-co-NIPAM) (PMON). ### Claim 5 (depends on 1) The bioabsorbable stent of to claim 1, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 6 (depends on 1) The bioabsorbable stent of to claim 1, wherein the biodegradable material and PPCP are blended using a solvent casting technique. ### Claim 7 (depends on 6) The bioabsorbable stent of to claim 6, wherein the solvent casting technique includes a solvent selected from dichloromethane and methanol. ### Claim 8 (depends on 1) The bioabsorbable stent of to claim 1, wherein the bioabsorbable stent is fabricated by processing a tube made of the blend. ### Claim 9 (depends on 1) The bioabsorbable stent of to claim 1, wherein the stent is fabricated by processing a cast film made of the blend. ### Claim 10 A bioabsorbable stent, wherein the bioabsorbable stent is made from a blend, the blend comprising a phosphorylcholine group containing copolymer (PPCP) that is absorbable in blood. ### Claim 11 (depends on 10) The bioabsorbable stent of claim 10, wherein the PPCP is a water-soluble amphiphilic copolymer. ### Claim 12 (depends on 10) The bioabsorbable stent of claim 10, wherein the PPCP is prepared by copolymerization of a 2-methacryloyloxethyl phosphoroylcholine (MPC) unit with a monomer selected from the group consisting of methyl methacrylate (MMA), ethyl methacrylate (EMA), butyl methacrylate (BMA), 2-ethylhexyl methacrylate (EHMA), lauryl methacrylate (LMA), hydroxyl-ethyl methacrylate (HEMA), choline methacrylate (CMA), poly(ethylene gycol) acrylate (PEGA), PEG methacrylate, 2-(methacryloxy)ethyl phosphorylcholine (MFC), N-vinyl pyrrolidone (VP), methacrylic acid (MA), acrylic acid (AA), hydroxypropyl methacrylate (HPMA), hydroxypropyl methacrylamide, 3-trimethylsilyl-propyl methacrylate (TMSPMA), p-nitrophenyloxycarbonyl(polyoxyethylene) methacrylate (MEONP), N-isopropylacrylamide (NIPAM), N-octyl acrylamide, and a combination thereof. ### Claim 13 (depends on 10) The bioabsorbable stent of claim 10, wherein the PPCP is selected from the group consisting of poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) (PMB), poly(MPC-co-BMA-co-methacrylic acid) (PMBAc), poly(MPC-co-BMA), poly(MPC-co-BMA-co-MEONP) (PMBN), and poly(MPC-co-n-octylacrylamide-co-NIPAM) (PMON). ### Claim 14 (depends on 10) The bioabsorbable stent of claim 10, wherein the blend further comprises a bioabsorbable polymer. ### Claim 15 (depends on 14) The bioabsorbable stent of claim 14, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 16 (depends on 14) The bioabsorbable stem of claim 14, wherein the bioabsorbable polymer comprises L-lactic acid. ### Claim 17 (depends on 15) The bioabsorbable stent of claim 15, wherein the bioabsorbable polymer is PLLA (poly(L-lactide). ### Claim 18 (depends on 14) The bioabsorbable stent of claim 14, wherein the bioabsorbable polymer and PPCP are blended using a solvent casting technique. ### Claim 19 (depends on 18) The bioabsorbable stent of claim 18, wherein the solvent casting technique includes a solvent selected from dichloromethane and methanol. ### Claim 20 (depends on 2) The bioabsorbable stent of claim 2, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 21 (depends on 3) The bioabsorbable stent of claim 3, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 22 (depends on 4) The bioabsorbable stent of claim 4, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 23 (depends on 11) The bioabsorbable stent of claim 11, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 24 (depends on 12) The bioabsorbable stent of claim 12, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 25 (depends on 13) The bioabsorbable stent of claim 13, wherein the blend comprises 0.5% to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 26 (depends on 16) The bioabsorbable stent of claim 16, wherein the blend comprises 0.5 wt % to 8 wt % PPCP with respect to the total weight of the blend. ### Claim 27 (depends on 21) The bioabsorbable stent of claim 21, wherein the bioabsorbable polymer is PLLA (poly(L-lactide). ### Claim 28 (depends on 22) The bioabsorbable stent of claim 22, wherein the bioabsorbable polymer is PLLA (poly(L-lactide). ### Claim 29 (depends on 24) The bioabsorbable stent of claim 24, wherein the blend further comprises PLLA (poly(L-lactide). ### Claim 30 (depends on 25) The bioabsorbable stent of claim 25, wherein the blend further comprises PLLA (poly(L-lactide).